Publications by authors named "Patrick Burnett"

Claim this Profile

Mentions over time

Mentions by platform

Video Views

272

Total Likes

4

Extended Reach

1,262

Social Features

4
P
Pooled Results of Two Randomized Phase III Trials Evaluating VP-102, a Drug-Device Combination Product Containing Cantharidin 0.7% (w/v) for the Treatment of Molluscum Contagiosum.
Lawrence F Eichenfield, Elaine Siegfried, Pearl Kwong, Mark McBride, Jayson Rieger, David Glover, Cynthia Willson, Matthew Davidson, Patrick Burnett, Melissa Olivadoti

Am J Clin Dermatol· March 2021

Videos about Article: user

1 2 3 2

View All Article and Social Media Activity
R
Roflumilast Cream 0.3% in Patients with Chronic Plaque Psoriasis: Pooled PASI and PASI-HD Results from the DERMIS Phase III Trials.
Kim A Papp, James Q Del Rosso, Mark G Lebwohl, Melinda J Gooderham, Adelaide A Hebert, Patrick Burnett

Dermatol Ther (Heidelb)· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-Term Safety and Efficacy of Roflumilast Foam 0.3% in Patients with Seborrheic Dermatitis: A Phase II, Open-Label Trial of up to 52 Weeks.
Andrew F Alexis, Michael Bukhalo, Fran E Cook-Bolden, James Q Del Rosso, Zoe D Draelos, Patrick Burnett

Am J Clin Dermatol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Early Evidence of Safety, Clinical Benefit, and Pharmacokinetics of Roflumilast Cream 0.3% Once Daily for Treatment of Mild or Moderate Plaque Psoriasis in Children Aged 2-11 Years.
Adelaide A Hebert, Shireen V Guide, Vlada Groysman, Mercedes E Gonzalez, Daisy Blanco, Patrick Burnett

Pediatr Dermatol· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Roflumilast Foam, 0.3%, for Psoriasis of the Scalp and Body: The ARRECTOR Phase 3 Randomized Clinical Trial.
Melinda J Gooderham, Javier Alonso-Llamazares, Jerry Bagel, Neal Bhatia, Michael Bukhalo, Patrick Burnett

JAMA Dermatol· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tape-strip profiling identifies unique immune and lipid dysregulation in patients with seborrheic dermatitis.
Benjamin Ungar, Meredith Manson, Madeline Kim, Digpal Gour, Panipak Temboonnark, Patrick Burnett

J Am Acad Dermatol· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety of Once-Daily Roflumilast Cream 0.05% in Pediatric Patients Aged 2-5 Years With Mild-to-Moderate Atopic Dermatitis (INTEGUMENT-PED): A Phase 3 Randomized Controlled Trial.
Lawrence F Eichenfield, Rocco Serrao, Vimal H Prajapati, John C Browning, Lisa Swanson, Patrick Burnett

Pediatr Dermatol· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-Term Safety and Efficacy with Roflumilast Cream 0.15% in Patients Aged ≥6 Years with Atopic Dermatitis: A Phase 3 Open-Label Extension Trial.
Eric L Simpson, Lawrence F Eichenfield, Kim A Papp, Seth B Forman, Adelaide A Hebert, Patrick Burnett

Dermatitis· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Roflumilast Cream, 0.15%, for Atopic Dermatitis in Adults and Children: INTEGUMENT-1 and INTEGUMENT-2 Randomized Clinical Trials.
Eric L Simpson, Lawrence F Eichenfield, Javier Alonso-Llamazares, Zoe D Draelos, Laura K Ferris, Patrick Burnett

JAMA Dermatol· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessment of the Vehicle for Roflumilast Cream Compared to a Ceramide-Containing Moisturizing Cream in Mild Eczema.
Zoe Diana Draelos, Robert C Higham, David W Osborne, Melissa S Seal, Patrick Burnett

J Drugs Dermatol· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term safety and effectiveness of roflumilast cream 0.3% in adults with chronic plaque psoriasis: A 52-week, phase 2, open-label trial.
Linda Stein Gold, David N Adam, Lorne Albrecht, Javier Alonso-Llamazares, Laura K Ferris, Patrick Burnett

J Am Acad Dermatol· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Roflumilast foam 0.3% for adolescent and adult patients with seborrheic dermatitis: A randomized, double-blinded, vehicle-controlled, phase 3 trial.
Andrew Blauvelt, Zoe D Draelos, Linda Stein Gold, Javier Alonso-Llamazares, Neal Bhatia, Patrick Burnett

J Am Acad Dermatol· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
When Patient Diversity Informs Formulation: Reimagining Treatment for Seborrheic Dermatitis.
Meredith Tyree Polaskey, Heather Woolery-Llloyd, David Osborne, Patrick Burnett, Diane Hanna

Dermatol Ther (Heidelb)· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Putting the Formulation Back in Foam: Optimizing Seborrheic Dermatitis Treatment Across Diverse Hair Types.
Raj Chovatiya, Meredith Tyree Polaskey, Edward Lain, Todd Schlesinger, Heather Woolery-Llloyd, Patrick Burnett

J Clin Aesthet Dermatol· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
IgE Depletion with Ligelizumab Does Not Significantly Improve Clinical Symptoms in Patients with Moderate-to-Severe Atopic Dermatitis.
Christine Bangert, Christian Loesche, Hans Skvara, Regina Fölster-Holst, Jean-Philippe Lacour, Patrick Burnett

J Invest Dermatol· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Once-daily roflumilast foam 0.3% for scalp and body psoriasis: a randomized, double-blind, vehicle-controlled phase IIb study.
Leon H Kircik, Javier Alonso-Llamazares, Neal Bhatia, Michael Bukhalo, Alim R Devani, Patrick Burnett

Br J Dermatol· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of Roflumilast Foam, 0.3%, in Patients With Seborrheic Dermatitis: A Double-blind, Vehicle-Controlled Phase 2a Randomized Clinical Trial.
Matthew J Zirwas, Zoe D Draelos, Janet DuBois, Leon H Kircik, Angela Y Moore, Patrick Burnett

JAMA Dermatol· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of roflumilast cream for chronic plaque psoriasis with facial/neck and intertriginous area involvement: a post hoc analysis from a randomized controlled trial.
Zoe D Draelos, David N Adam, H Chih-Ho Hong, Mark G Lebwohl, Charles W Lynde, Patrick Burnett

Br J Dermatol· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics of Roflumilast Cream in Chronic Plaque Psoriasis: Data from Phase I to Phase III Studies.
Archie W Thurston, David W Osborne, Scott Snyder, Robert C Higham, Patrick Burnett

Am J Clin Dermatol· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of New Zealand Blackcurrant Extract on Sequential Performance Testing in Male Rugby Union Players.
Patrick J M Burnett, Mark E T Willems

Sports (Basel)· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of Roflumilast Cream vs Vehicle Cream on Chronic Plaque Psoriasis: The DERMIS-1 and DERMIS-2 Randomized Clinical Trials.
Mark G Lebwohl, Leon H Kircik, Angela Y Moore, Linda Stein Gold, Zoe D Draelos, Patrick Burnett

JAMA· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
COVE-1: A Phase 2, Open-Label Study to Evaluate Efficacy and Safety and the Optimal Regimen of VP-102, a Proprietary Drug-Device Product Containing Topical Cantharidin (0.7% w/v) Under Occlusion for the Treatment of Common Warts.
Scott Guenthner, Wendy McFalda, Pearl Kwong, Kimberly Eads, Morgan McCafferty, Patrick Burnett

Dermatol Ther (Heidelb)· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and Efficacy of VP-102 (Cantharidin, 0.7% w/v) in Molluscum Contagiosum by Body Region: Pooled Analyses from Two Phase III Randomized Trials.
Lawrence F Eichenfield, Pearl Kwong, Mercedes E Gonzalez, Albert Yan, Pieter D'Arnaud, Patrick Burnett

J Clin Aesthet Dermatol· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase 2 Open-Label Study to Evaluate VP-102 for the Treatment of Molluscum Contagiosum.
Sahra Niazi, Bradford Brabec, Luke Anschutz, Cynthia Willson, Matthew Davidson, Patrick Burnett

J Drugs Dermatol· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and Efficacy of VP-102, a Proprietary, Drug-Device Combination Product Containing Cantharidin, 0.7% (w/v), in Children and Adults With Molluscum Contagiosum: Two Phase 3 Randomized Clinical Trials.
Lawrence F Eichenfield, Wendy McFalda, Bradford Brabec, Elaine Siegfried, Pearl Kwong, Patrick Burnett

JAMA Dermatol· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis